Skip Navigation
Johns Hopkins Bloomberg School of Public HealthCAAT

1992 Recognition Awards

Andrew N. Rowan, D.Phil.

Andrew Rowan, director of the Tufts Center for Animals and Public Policy, has been key in changing the attitude within the scientific community from "if an alternative can be developed" to "when we develop an alternative." As the author of position papers and fact sheets which became the rational foundation for campaigns to develop alternatives, he made it possible for advocates to argue for alternatives with thorough, documented critiques of traditional animal tests and realistic opportunities for change.

His facilitation of symposia and workshops with representatives from corporate, government, academic and animal protection sectors provides an opportunity for the meshing of technology with public policy. His personal approach provides an atmosphere where groups with traditionally opposing points of view find common ground.

Dr. Rowan has spoken at conferences on alternatives in Europe, Australia, Africa and North America and produced numerous articles in scientific publications. His book on animal research is a source of accurate information and analysis. He also serves on the CAAT Advisory Board.

Gerhard Zbinden, M.D., FRCPath.

Gerhard Zbinden has been dedicated to scientific advancement of in vitro methods and toxicology, with an overriding consideration for the ethical basis of his decisions.

As the first scientist to present a rational basis for the elimination of the LD50 test, he has challenged animal testing procedures on scientific grounds at every opportunity.

Dr. Zbinden's primary interests are in the development of experimental models in toxicology, particularly in areas of cardiotoxicity, neurobehavioral toxicity and carcinogenicity. Most recently, he conducted extensive research on the application of in vitro techniques for the investigation of toxicological mechanisms.

Dr. Zbinden recently retired as professor of toxicology and director of the Institute of Toxicology of the Federal Institute of Technology and the University of Zurich. He had a distinguished career as head of the Department of Toxicology and Experimental Pathology for Hoffmann-LaRoche AG in Basel and vice president for research at the company's New Jersey laboratories.

Per Ottar Seglen, Ph.D.

Numerous methods have been developed to culture cells in vitro for toxicological research and testing. Few have had as major an impact on so many aspects of toxicology as the isolated hepatocyte techniques.

Per Seglen is recognized throughout the toxicology community as the individual who conducted the seminal research that made isolated hepatocyte culture the practical tool used today by toxicologists all over the world.

His outstanding efforts in the early 1970s demonstrated the validity of the model system and optimized the details of the procedure. Dr. Seglen has continued to contribute to our understanding of hepatic processes and their role in toxicology. His studies opened new and fertile areas for research in toxicology and carcinogenicity.

The Procter & Gamble Company

Development of alternatives is part of the corporate culture at The Procter & Gamble Company. The firm has established an extensive, intramural research program on alternatives covering eye irritation, skin irritation, skin allergy, genotoxicity, developmental toxicity, inhalation toxicity, respiratory allergy, computer modeling and non-invasive bioanalytical techniques.

Since 1989, it has spent more than $19 million to develop alternatives. A University Animal Alternatives Research Program was established in 1989 to promote alternatives research and will provide a total of $450,000 in grants in this fiscal year. Research proposals at outside laboratories complement Procter & Gamble's own programs. Seed money fosters workshops, symposia and special publications.

In addition, Procter & Gamble scientists have published more than 70 papers and made more than 150 presentations on alternatives. The company newsletter "Alternatives Alert" promotes communication on alternatives development among in-house life scientists. And Procter & Gamble representatives have testified before regulatory agencies worldwide to promote their acceptance of alternatives.